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Broadly speaking, a rare disease is any disease that affects a small percentage of people in a population.
Although there is no more specific, widely accepted definition of a rare disease, the European Commission
on Public Health defines rare diseases as “life-threatening or chronically debilitating diseases, which are
of such low prevalence that special combined efforts are needed to address them” [1]. The term “low
prevalence” is defined as generally meaning fewer than one in 2000 people [1, 2]. With a conservative
estimate that primary or secondary lung involvement occurs in ∼5% of rare diseases (>6000 types),
approximately 1–2 million people in the European Union are likely to be affected by rare pulmonary
diseases. Therefore, cumulatively, rare pulmonary diseases represent a significant burden of disease, with
many of these being severe conditions that result in premature death or major morbidity.
Patients with rare diseases have traditionally lived a lonely existence. Rare diseases are often poorly studied,
attract little attention from researchers and clinicians alike, and specific therapy may not be available, thus
leading to the term “orphan diseases” being used synonymously to describe these conditions. In order to
advance our knowledge and improve outcomes in rare diseases, collective efforts are required not just at a
national level but also encompassing international collaboration.
To provide a voice for rare disease patients in Europe, Rare Disease Day (fig. 1) was first launched in 2008
by the European Organisation for Rare Diseases (EURORDIS), a nongovernment alliance of >600 rare
disease patient organisations in >50 countries, covering >4000 diseases [3]. Rare Disease Day takes place
on the last day of February each year, and thus is held on the 29th, a rare day, in leap years (and on the
28th in other years). Even though this campaign started as a European event, it is now held in many
countries around the world. It has progressively gathered momentum and has now become a world
phenomenon, with the USA joining in 2009. Participation in 2014 included a record-breaking 84 countries
around the world.
The main objective of EURORDIS and Rare Disease Day is to improve the quality of life of people living
with rare diseases through advocacy, support for research and medicine development, facilitating
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networking among patient groups, raising awareness, and many other actions designed to reduce the
impact of rare diseases on the lives of patients and family [3].
Partly due to greater awareness in the medical community and advancement of diagnostic techniques,
registry data indicated that the incidence and prevalence of rare pulmonary diseases appear to be
increasing. For instance, the incidence of pure idiopathic pulmonary arterial hypertension (PAH) has
increased from 0.7 to 1.1 cases per million persons during the first decade of the 21st century in the UK
and Ireland, and PAH (as a collective group) has a minimum prevalence and incidence of 15 per million
adult inhabitants and 2.4 cases per million adult inhabitants per year in France, respectively [4, 5].
Similarly, the estimated prevalence of lymphangioleiomyomatosis (LAM) in 2011 was one case per million
people, while in 2013 the prevalence was reported to be 5.6 cases per million [6]. In the last 20 years, the
knowledge of some rare pulmonary conditions has markedly improved and new therapies are now available
that may be effective in changing the clinical course of several illness, such as PAH [7], chronic
thromboembolic pulmonary hypertension [8–12], pulmonary vasculitis [13], bronchiolitis [14–16], LAM
[17–20], pulmonary alveolar proteinosis [21, 22], α1-antitrypsin deficiency [23], pulmonary Langerhans cell
histiocytosis [24, 25] and, more recently (and after several negative trials), idiopathic pulmonary fibrosis
(IPF) [26–30]. New horizons of hope are now offered to patients suffering from rare pulmonary diseases.
With the organisation of courses and dedicated symposiums during the European Respiratory Society
(ERS) International Congress, and the publication of articles in all ERS publications, our society plays a key
role in the process of advancing medical research in this field. Moreover, the ERS also promotes and
supports guidelines and statements, funds fellowship programmes and many others activities (some in
partnership with patients’ associations), and coordinates actions against rare pulmonary diseases with
European health authorities. In recent years, the European Respiratory Journal (ERJ) has focussed particular
attention on rare pulmonary diseases and orphan drugs [26, 31–35]. Several important articles dealing with
everything from basic science to clinical research have been published in the field of rare pulmonary
diseases such as IPF, LAM, PAH or pulmonary Langerhans cell histiocytosis [14–17, 21–24, 26, 36].
The critical role of patient associations has been clearly recognised in recent years. A strong partnership
with medical societies like the ERS is crucial to establishing successful political actions, and to improving
communication with healthcare professionals, patients suffering from rare diseases and their relatives.
Strong action is needed at the European level to overcome all the differences in the national health systems
that can discriminate against patients with rare conditions and limit their access to treatment. It is also
important to identify uniform criteria to be adopted by referral centres in the various European countries;
moreover, in the spirit of the “free circulation of patients within the European member states”, it is also
important to create, for selected cases, some dedicated European referral centres and networks that can
manage patients and, therefore, accumulate enough experience to maximise the skills in the management
of particularly rare diseases.
FIGURE 1 The Rare Disease Day logo.
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In February 2015, the ERS will endorse the Sixth International Meeting on Pulmonary Rare Diseases and
Orphan Drugs, which will take place on Rare Disease Day in Milan, Italy. This international conference,
the first of which was held 10 years ago, is entirely dedicated to the management of rare pulmonary
parenchymal and vascular diseases, and rare variants of more common pulmonary conditions (such as
severe refractory asthma and α1-antitrypsin deficiency emphysema).
This conference is the only European event dedicated to these challenging tasks, and it highlights that rare
pulmonary diseases represent an important field of medicine not only for selected pulmonologists who are
skilled in diagnosing and treating particular groups of these diseases, but also for all respiratory physicians.
Dissemination among experts in different areas of clinical and basic research in respiratory medicine is
part of the stimulating challenge of providing new insights, helping patients and supporting healthcare
professionals. Topics that will be discussed during the conference include basic science, new genetic
studies, molecular advances, and issues related to trial design and surrogate end-points in rare diseases
studies; moreover, findings that will facilitate the development of new therapeutic options for patients
affected by these conditions will be presented.
The Sixth International Meeting on Pulmonary Rare Diseases and Orphan Drugs will take place in Milan
on the February 27–28, 2015, just a few weeks before this city will play host to the World Expo 2015. Expo
2015 will explore the theme “feeding the planet, energy for life”, a topic of great importance for the future
of our lives and for world health: this world exposition is expected to attract >20 million visitors from all
over the world.
Proceedings from past annual meetings and several selected reports from the 2013 meeting have previously
been published in the European Respiratory Review (ERR) [37, 38]. Some manuscripts from the 2015
conference will published in the ERR. In addition, later this year, the ERJ will published a series of articles
from the 2015 conference that will discuss rare pulmonary diseases and orphan drugs, and cover various
topics (e.g. IPF, LAM, PAH and pulmonary veno-occlusive disease).
Crucial issues in research on rare diseases include solid and transparent collaborations with the
pharmaceutical industry, fostered by orphan drug legislation, and development of independent and
unsponsored investigations, supported by national, European and international funding. In this sense,
PAH represents an important example with an outstanding international network of PAH clinicians and
researchers, ranging from basic science to clinical studies, working in close partnership with
pharmaceutical companies. In the near future, several programmes, including Horizon 2020, which is
supported by the European Union, will offer important opportunities to promote research in the whole
field of pulmonary medicine.
We hope that this conference and related articles will help our readers understand the main purposes of
the discussions arising during the Milan conference and will increase awareness of rare pulmonary
diseases. The International Meetings on Pulmonary Rare Diseases and Orphan Drugs are scheduled every
other year because this area of medicine is growing rapidly and attracts increasing attention from the
entire medical community. For the upcoming Sixth International Meeting on Pulmonary Rare Diseases
and Orphan Drugs, we have decided to paraphrase the Expo motto and adopt our own: “feeding the
breath, energy for life!”.
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